Journal
JOURNAL OF DRUG TARGETING
Volume 16, Issue 5, Pages 424-435Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10611860802088598
Keywords
Docetaxel; PLGA-mPEG; nanoparticles; pharmacokinetics; solid tumor
Categories
Ask authors/readers for more resources
Purpose: The aim of this study was to investigate the ability of PEGylated poly(D,L-lactide-co-glycolide) nanoparticles (NPs) to deliver Docetaxel (DTX) (an anticancer agent) to solid tumors. Methods: PLGA-mPEG diblock copolymers were synthesized by ring opening polymerization reaction and characterized by H-1 NMR, FT-IR and gel permeation chromatography. NPs, with a smooth spherical shape and near 100 nm size were prepared using the emulsion solvent evaporation technique and characterized. The drug release rate was investigated in acidic and physiological media (phosphate buffer saline, pH 5.0 and 7.4). The therapeutic efficacy and biocompatibility of NP formulations were evaluated for in vitro cytotoxicity by MTTassay using MCF-7 and C26 cell lines. The pharmacokinetic and biodistribution studies were performed on C26 tumor bearing mice. The antitumor efficacy of DTX NP formulations on C26 tumor bearing mice was investigated. Results: DTX-loaded PEGylated NPs increased the drug's biological half-life while providing substantial accumulation at the solid tumors. PEGylated NPs appear to be a promising alternate carrier for DTX having greater efficacy in inhibiting tumor growth.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available